DK1679074T3 - Terapeutisk middel til keratoconjunktive forstyrrelser - Google Patents

Terapeutisk middel til keratoconjunktive forstyrrelser

Info

Publication number
DK1679074T3
DK1679074T3 DK04793171.2T DK04793171T DK1679074T3 DK 1679074 T3 DK1679074 T3 DK 1679074T3 DK 04793171 T DK04793171 T DK 04793171T DK 1679074 T3 DK1679074 T3 DK 1679074T3
Authority
DK
Denmark
Prior art keywords
therapeutic agent
ylmethoxy
benzimidazol
thiazolidine
dione
Prior art date
Application number
DK04793171.2T
Other languages
English (en)
Inventor
M Nakamura
S Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1679074T3 publication Critical patent/DK1679074T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04793171.2T 2003-10-24 2004-10-22 Terapeutisk middel til keratoconjunktive forstyrrelser DK1679074T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003364864 2003-10-24
PCT/JP2004/016063 WO2005039574A1 (ja) 2003-10-24 2004-10-22 角結膜障害の治療剤

Publications (1)

Publication Number Publication Date
DK1679074T3 true DK1679074T3 (da) 2011-03-21

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04793171.2T DK1679074T3 (da) 2003-10-24 2004-10-22 Terapeutisk middel til keratoconjunktive forstyrrelser

Country Status (16)

Country Link
US (1) US7358255B2 (da)
EP (1) EP1679074B1 (da)
JP (1) JP4217832B2 (da)
KR (1) KR101154175B1 (da)
CN (1) CN1870997B (da)
AT (1) ATE490771T1 (da)
CA (1) CA2543452C (da)
CY (1) CY1111191T1 (da)
DE (1) DE602004030470D1 (da)
DK (1) DK1679074T3 (da)
ES (1) ES2357801T3 (da)
PL (1) PL1679074T3 (da)
PT (1) PT1679074E (da)
SI (1) SI1679074T1 (da)
TW (1) TWI343256B (da)
WO (1) WO2005039574A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348329B2 (en) * 2003-10-29 2008-03-25 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
KR101508020B1 (ko) * 2007-05-21 2015-04-06 센주 세이야꾸 가부시키가이샤 Ｐｐａｒδ 아고니스트 함유 의약
CA2689663C (en) 2007-06-13 2016-08-09 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US20110092524A1 (en) * 2008-02-25 2011-04-21 Santen Pharmaceutical Co., Ltd. Agent for Enhancing Corneal Epithelial Barrier Function
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20220015492A (ko) * 2010-03-10 2022-02-08 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
PL2574168T3 (pl) 2010-05-21 2016-10-31 Preparaty inhibitora kinazy janusowej do stosowania miejscowego
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
PE20200175A1 (es) 2012-11-15 2020-01-24 Incyte Holdings Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
CA3155500A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264586B1 (en) 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
JP3072227B2 (ja) * 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) * 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IL142649A (en) 1996-12-31 2004-12-15 Reddy Research Foundation Azole derivatives
JPH11130675A (ja) * 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
JP2001039976A (ja) * 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
US7348329B2 (en) 2003-10-29 2008-03-25 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder

Also Published As

Publication number Publication date
CA2543452A1 (en) 2005-05-06
CY1111191T1 (el) 2015-06-11
PL1679074T3 (pl) 2011-05-31
TWI343256B (en) 2011-06-11
EP1679074B1 (en) 2010-12-08
KR101154175B1 (ko) 2012-06-14
TW200518750A (en) 2005-06-16
CN1870997A (zh) 2006-11-29
WO2005039574A8 (ja) 2005-06-23
SI1679074T1 (sl) 2011-04-29
US20070060628A1 (en) 2007-03-15
PT1679074E (pt) 2011-03-03
JP2005145961A (ja) 2005-06-09
ES2357801T3 (es) 2011-04-29
WO2005039574A1 (ja) 2005-05-06
EP1679074A4 (en) 2009-03-25
ATE490771T1 (de) 2010-12-15
CN1870997B (zh) 2011-05-04
JP4217832B2 (ja) 2009-02-04
US7358255B2 (en) 2008-04-15
EP1679074A1 (en) 2006-07-12
DE602004030470D1 (de) 2011-01-20
KR20060100440A (ko) 2006-09-20
CA2543452C (en) 2012-03-13

Similar Documents

Publication Publication Date Title
DK1679074T3 (da) Terapeutisk middel til keratoconjunktive forstyrrelser
PE20090837A1 (es) Nuevos compuestos quimicos
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
DE60316810T2 (de) 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
PE20051146A1 (es) Compuestos heterociclicos anticitocina
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20081530A1 (es) Nuevos compuestos 617
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20141375A1 (es) Activadores de glucoquinasa
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
HRP20141048T1 (hr) Spojevi, pripravci i metode
PE20081532A1 (es) Compuestos novedosos
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
RU2008129723A (ru) Ингибиторы ccr9 активности
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
HRP20140588T1 (hr) Spojevi kondenziranog prstena i njihova uporaba
PE20080271A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)